Sen. Kamala Harris (D-CA) has walked back her answer about eliminating private health insurance from the Democratic debate on Thursday. Harris said she misunderstood the question about whether the candidates would favor eliminating private coverage — she said yes — and meant that she would enroll in a government plan herself. (HuffPost)

Former Food and Drug Administration Commissioner Scott Gottlieb has joined Pfizer’s board of directors. He can advise the company on biosimilars and generic drug approvals, two issues he advocated for during his time at the FDA. Gottlieb resigned from the FDA in April. (CNBC)

Pfizer’s biosimilar to Roche’s Avastin has been approved by the FDA. The biosimilar, Zirabev, is a treatment for five types of cancer including colorectal and lung. This is the second biosimilar to Avastin after Amgen’s Mvasi was approved in 2017. (Reuters)

A lawsuit claims Google didn’t protect patient health information. The tech giant and the University of Chicago were researching and building tools to “better understand disease.” During their partnership, they left doctors’ notes and date stamps in patient medical records. (CNBC)

MM&M asked the healthcare industry to share how they deal with trolls on social media. Here’s a list of their best practices and strategies. (MM&M)